Mr. Ahmad Doroudian reports

BETTERLIFE PHARMA ANNOUNCES DEBT CONVERSIONS

Betterlife Pharma Inc. has issued 2,153,205 common shares and 2,153,205 share purchase warrants in connection with the conversion of principal and accrued interest on convertible debentures totalling $215,320.55. Each share purchase warrant entitles the holder to acquire one common share at an exercise price of 10 cents per share and will expire between Sept. 27, 2026, and Oct. 29, 2026.

About Betterlife Pharma Inc.

Betterlife Pharma is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling (investigational new drug) studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. Betterlife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

Betterlife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

We seek Safe Harbor.